Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2.

Authors :: Opstal, Tjerk S.J.
van Broekhoven, Amber
Fiolet, Aernoud T.L.
Mosterd, Arend
Eikelboom, John W.
Nidorf, Stefan M.
Thompson, Peter L.
Budgeon, Charley A.
Bartels, Louis
de Nooijer, Ron
Bax, Willem A.
Tijssen, Jan G.P.
El Messaoudi, Saloua
Cornel, Jan H.
Source :: Circulation. 2/22/2022, Vol. 145 Issue 8, p626-628. 3p.
Publication Year :: 2022
Abstract: Keywords: cardiovascular diseases; colchicine; coronary artery disease; inflammation EN cardiovascular diseases colchicine coronary artery disease inflammation 626 628 3 02/24/22 20220222 NES 220222 Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands (T.S.J.O. A.v.B. The main drivers of the primary composite end point, ischemia-driven coronary revascularization and myocardial infarction, were both consistently reduced by long-term colchicine treatment. The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. [Extracted from the article]

Full Text Access

Tools